Focal Coronary Disease Predicts Greater Angina Relief After Stenting

Physiological Phenotyping in Stable Coronary Artery Disease

The management of stable coronary artery disease relies on a foundation of optimal medical therapy, including antiplatelet agents such as aspirin (75 to 150 mg daily) and lipid-lowering protocols to mitigate the risk of occlusive vascular events [1, 2]. While percutaneous coronary intervention (a catheter-based procedure to open narrowed coronary arteries) is frequently employed to alleviate angina, large-scale trials have shown that coronary artery bypass grafting remains the standard for multi-vessel disease due to lower rates of major adverse cardiac events [3]. Furthermore, a meta-analysis of 6,428 patients found that the use of glycoprotein IIb/IIIa inhibitors (intravenous agents that block the final pathway of platelet aggregation) during elective intervention reduced 30-day major adverse cardiac events (risk ratio 0.58; 95% confidence interval, 0.39 to 0.86; p < 0.01) [4]. Current clinical guidelines emphasize the necessity of rigorous diagnostic evaluation to guide these therapeutic strategies, yet the heterogeneity of patient responses to intervention remains a significant challenge in daily practice [5, 6]. Recent advancements in intracoronary physiology have allowed for a more granular assessment of how pressure drops are distributed across a vessel, moving beyond simple stenosis severity (the physical degree of vessel narrowing). A new study now investigates whether these specific physiological patterns can predict the actual symptomatic benefit of intervention when measured against a placebo control.

Quantifying Focal and Diffuse Disease Patterns

The ORBITA-2 trial was a randomized placebo-controlled trial of angioplasty for stable angina designed to determine if the distribution of coronary disease influences the efficacy of percutaneous coronary intervention. To achieve this, researchers utilized prerandomization nonhyperemic pressure wire pullback assessments. This specific technique measures pressure changes along the entire length of a coronary artery as the wire is slowly withdrawn, providing a physiological map of resistance without the need for vasodilator drugs like adenosine. This approach allows clinicians to distinguish between discrete, localized narrowings and more gradual, continuous pressure losses that occur over longer segments of the vessel. To ensure objective categorization of these physiological maps, seven blinded interventional cardiologists independently reviewed each pullback trace. These reviewers categorized the disease patterns into three distinct groups: focal, diffuse, or mixed. The researchers then assigned numerical values to these classifications to create a standardized metric, where focal disease received a value of 1, diffuse disease received a 0, and mixed patterns were assigned 0.5. The overall disease pattern score for each vessel was determined by the mean of the seven reviewers' scores. Under this rigorous scoring system, a mean score greater than 0.5 was considered focal, while a score of 0.5 or less was categorized as diffuse. The study analyzed a total of 245 patients with 300 target vessel pullbacks, providing a robust dataset to evaluate how these anatomical phenotypes respond to treatment. By quantifying the disease pattern before randomization, the investigators could precisely correlate the physiological nature of the lesion with the patient's subsequent symptomatic response. This methodology moves beyond traditional angiography by using pressure-based data to define whether a patient's angina is driven by a single, treatable point of resistance or a more systemic, longitudinal vessel pathology that may be less amenable to mechanical stenting.

Symptomatic Relief and Functional Capacity

The researchers found that the physiological pattern of coronary disease significantly influenced the degree of symptomatic relief following percutaneous coronary intervention. After adjusting for the prerandomization nonhyperemic pressure ratio (a baseline measure of coronary pressure taken under resting conditions), patients with focal disease experienced a greater improvement in their angina symptom score compared to those with diffuse disease patterns. This benefit was quantified by an odds ratio of 1.80 (95% credible interval [CrI]: 1.48 to 2.18), with a probability of benefit exceeding 99.9%. Similarly, the reduction in the frequency of daily angina was more pronounced in the focal group. For these patients, percutaneous coronary intervention resulted in a greater reduction in daily episodes of angina than in the diffuse group, yielding an odds ratio of 1.55 (95% CrI: 1.26 to 1.89) and a probability of benefit greater than 99.9%. Beyond subjective symptom reporting, the study demonstrated that disease morphology predicted improvements in objective functional capacity and standardized clinical classifications. Focal disease predicted a greater placebo-controlled benefit in exercise treadmill time, with a probability of interaction (a statistical measure of how much the treatment effect depends on the disease pattern) exceeding 99.9%. Clinical severity, as measured by the Canadian Cardiovascular Society class, also showed a differential response, where focal lesions were associated with a greater placebo-controlled benefit, evidenced by a probability of interaction of 99.0%. Furthermore, the Seattle Angina Questionnaire angina frequency score, which provides a standardized assessment of how often patients experience chest pain, showed a significantly higher likelihood of improvement in the focal group compared to the diffuse group, with a probability of interaction of 99.5%. These findings suggest that the physiological distribution of atherosclerosis is a critical determinant of the functional gains achieved through mechanical revascularization.

Clinical Utility and Quality of Life Metrics

Historically, unblinded studies have demonstrated superior procedural and clinical outcomes of percutaneous coronary intervention in focal compared with diffuse coronary artery disease. However, data from the first placebo-controlled study did not demonstrate a differential impact of disease pattern on symptom endpoints, creating uncertainty regarding the predictive value of lesion morphology. To provide more definitive evidence, the ORBITA-2 researchers utilized Bayesian proportional odds modeling (a statistical method that estimates the probability of falling into different categories of a ranked outcome). This analysis, which included 245 patients and 300 target vessel pullbacks, adjusted for the prerandomization nonhyperemic pressure ratio, defined as the baseline ratio of distal coronary pressure to aortic pressure measured under resting conditions. The physiological distribution of atherosclerosis also proved to be a significant predictor of overall health status. Focal disease predicted a greater placebo-controlled benefit in the EuroQol Group 5-Dimensions 5-Level questionnaire (a standardized instrument for measuring generic health status across five domains including mobility and pain), with a probability of interaction of 95.1%. While symptomatic and quality-of-life metrics showed strong correlation with disease patterns, the evidence was less robust regarding objective stress testing. There was weaker evidence of an interaction between disease pattern and the placebo-controlled impact of percutaneous coronary intervention on improvement in dobutamine stress echocardiography scores, with a probability of interaction of 83%. These findings suggest that physiological patterns of disease may be useful to guide treatment decision making when percutaneous coronary intervention is considered for symptom relief. By identifying focal disease through pressure wire pullback assessments, clinicians can better select candidates likely to achieve the most significant gains in functional capacity and quality of life. This evidence shifts the focus toward physiological phenotyping as a primary determinant of the symptomatic efficacy of mechanical revascularization in stable coronary artery disease.

References

1. Collaboration AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002. doi:10.1136/bmj.324.7329.71

2. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2019. doi:10.1093/eurheartj/ehz455

3. Serruys PW, Morice M, Kappetein AP, et al. Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease. New England Journal of Medicine. 2009. doi:10.1056/nejmoa0804626

4. Brieger DG, Rao K, Nagaraja V, Bhindi R, Allahwala U. The use of glycoprotein IIb/IIIa inhibitors in elective PCI - A systematic review and meta-analysis of randomised trials.. Vascular pharmacology. 2025. doi:10.1016/j.vph.2025.107500

5. Collet J, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal. 2020. doi:10.1093/eurheartj/ehaa575

6. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal. 2019. doi:10.1093/eurheartj/ehz486